Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia

American Journal of Hematology

Volumn 90, Issue 1, 2015, Pages 82-83

  Pieri, Lisa ^a   Guglielmelli, Paola ^a   Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; GAMMA INTERFERON; HYDROXYUREA; INTERLEUKIN 15; INTERLEUKIN 2; JANUS KINASE 1; JANUS KINASE 2; RUXOLITINIB; JANUS KINASE; PYRAZOLE DERIVATIVE;

ADULT; ALOPECIA UNIVERSALIS; ARTICLE; BONE MARROW BIOPSY; CANCER PATIENT; CASE REPORT; CD8+ T LYMPHOCYTE; FEMALE; HUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; TREATMENT DURATION; YOUNG ADULT; ALOPECIA; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; ENZYMOLOGY; GENETICS; IMMUNOLOGY; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME;

ADULT; ALOPECIA; FEMALE; HUMANS; JANUS KINASES; PYRAZOLES; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919629361     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23871     Document Type: Article

References (5)

1. Gotlib J. JAK inhibition in the myeloproliferative neoplasms: Lessons learned from the bench and bedside. ASH Education Program Book 2013;2013:529-537.
2. Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: The clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014;123:3714-3719.
3. Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014;20:1043-1049.
4. Vannucchi AM. From palliation to targeted therapy in myelofibrosis. N Engl J Med 2010;363:1180-1182.
5. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014;120:513-520.